True Wealth Design’s aTyr Pharma ATYR Stock Holding History

True Wealth Design’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$277	Buy	464 +392	+544%	+$256	﹤0.01%	2374
2026 Q1	$57	Buy	+72	New	+$61	﹤0.01%	2555

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

True Wealth Design's ATYR Position: Q2 2026 in Review

True Wealth Design increased its aTyr Pharma (ATYR) stake by 544% in Q2 2026, buying an estimated $256 and bringing the position to 464 shares worth $277. The position accounts for ﹤0.01% of the portfolio, ranked #2374.

True Wealth Design first reported a position in ATYR in Q1 2026 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

True Wealth Design held 464 shares of aTyr Pharma worth $277 as of Q2 2026.
True Wealth Design bought 392 aTyr Pharma shares in Q2 2026, an estimated $256.
aTyr Pharma made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2374 holding.
True Wealth Design first reported a position in aTyr Pharma in Q1 2026 and has held it in 2 quarters since.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.